ClinicalTrials.gg
CompletedNCT01206764Updated Jun 24, 2019Results posted

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

A Phase 4 interventional study of RAD001 in Renal Cell Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-24.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2009, registered Sep 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
143
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing everolimus in Carcinoma, Renal Cell — 4 open to participants now, 7 under way, 2 of them phase 3. Everolimus · Carcinoma, Renal Cell.

Enrollment
7th of 48
143 · median 46
Started
2009
with 4 others
Phase 4
5 of 48
none open now
Registered
22nd of 48
by date
Lead sponsor
9 of 48
Novartis Pharmaceuticals

Among the 48 studies testing everolimus in Carcinoma, Renal Cell, this one is the 7th largest by enrollment, is one of 5 that started in 2009, is one of 5 in phase 4, and was the 22nd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

4 of the 48 studies testing everolimus in Carcinoma, Renal Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing everolimus in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Renal cell carcinoma (RCC) accounts for more than 200,000 new cases of cancer and over 100,000 cancer deaths annually in the World (Ferlay, et al., 2004). It is estimated that there were about 15,000 new cases of RCC in the region that excludes the Americas, European Union and Japan. Renal cell carcinomas arise from the proximal tubal epithelium are more common in males than in females with an overall lifetime risk of 1 in 75 and a median age of diagnosis of 65 years.

Everolimus (Certican®) has been approved since 2003 in more than 60 countries for the prevention of organ rejection in patients with renal and cardiac transplantation. Everolimus (RAD001) is a derivative of rapamycin, which acts as a signal transduction inhibitor. It targets mTOR, a key protein kinase regulating cell growth, proliferation, and survival. The mTOR pathway activity is modulated by the phosphatidylinositol-3-kinase (PI3K)/protein kinase B AKT (AKT) pathway, a pathway known to be deregulated in numerous human cancers. RAD001 (Afinitor®) has been investigated as an anticancer agent based on its potential to act:

  • directly on the tumor cells by inhibiting tumor cell growth and proliferation;
  • indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell hypoxia-inducible factor 1 (HIF-1) activity, VEGF production, and VEGF-induced proliferation of endothelial cells).

Primary: To evaluate the PFS rate over time.

Secondary:

  • To evaluate the disease control rate (stable disease [SD] + partial response [PR] + complete response [CR]);
  • To evaluate the objective response rate (ORR; where ORR = CR + PR) and duration;
  • To describe the safety profile of RAD001.
03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • RCC,
  • mTOR pathway,
  • angiogenesis,
  • PFS,
  • partial response [PR] + complete response [CR])
  • metastatic recurrent renal cell carcinoma
  • metastatic unresectable renal cell carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Patients may be entered in the study only if they meet all of the following criteria:

  • Age ≥18 years old;
  • Patients with advanced renal cell carcinoma with confirmed clear or non-clear cell histology, with or without nephrectomy, and with any MSKCC prognosis;
  • Prior cytokine therapy is permitted;
  • Patients with at least one at baseline as per the (RECIST) criteria. If skin lesions are reported as target lesions, they must be documented (at baseline and at every physical exam) using color photography and a measuring device (such as a caliper) in clear focus to allow the size of the lesion(s) to be determined from the photograph;
  • ≥3 months. Life expectancy should be judged in relation to other determining patient eligibility factors such as laboratory results, Performance Status, etc.;
  • Patients with a Karnofsky Performance Status ≥70%;
  • Adequate bone marrow function as shown by: (ANC) ≥1.5 x 109/L, ≥100 x 109/L, (Hb) >9 g/dL;
  • Adequate liver function: serum ≤1.5 x (ULN), (ALT), and aspartate transaminase (AST) ≤2.5 x ULN;
  • Adequate renal function: serum creatinine ≤1.5 x ULN;
  • Females of must have had a negative serum or urine pregnancy test 7 days prior to the administration of the study treatment start;
  • Patients who give a written obtained according to local guidelines.

Exclusion Criteria:Patients may not be entered into the study if they meet any of the following criteria:

  • Patients within 2 weeks post-minor surgery (e.g., herniorrhaphy), 4 weeks post-major surgery (e.g., intra-thoracic, intra-abdominal, or intra-pelvic) to avoid wound healing complications. Percutaneous require no waiting time prior to study entry;
  • Patients with a recent history of hemoptysis, ≥0.5 teaspoon of red blood;
  • Patients who have received prior systemic treatment for their RCC other than with cytokine therapy;
  • Patients who received prior therapy with a VEGF pathway inhibitor, such as sunitinib, sorafenib, and bevacizumab;
  • Patients who have previously received mTOR inhibitors (sirolimus, temsirolimus, everolimus, deferolimus);
  • History or clinical evidence of central nervous system (CNS) metastases. Note: Subjects who have previously-treated (surgery ± radiotherapy, radiosurgery, or gamma knife) and meet all 3 of the following criteria are eligible:

Are asymptomatic; Have had no evidence of active CNS metastases for ≥6 months prior to enrollment and; Have no requirement for or enzyme-inducing anticonvulsants (EIAC);

  • gastrointestinal abnormalities including, but not limited to: Malabsorption syndrome; Major resection of the stomach or small bowel that could affect the absorption of study drug; Active peptic ulcer disease; Inflammatory bowel disease; Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation; History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning of study treatment;
  • Patients receiving chronic systemic treatment with corticosteroids (dose of ≥10 mg/day methylprednisone equivalent) or another immune-suppressive agent. Inhaled and topical steroids are acceptable, as well as opotherapy after bilateral adrenal gland removal;
  • Patients with a known history of seropositivity;
  • Patients with hepatitis;
  • Patients with an active, bleeding diathesis. Patients may use coumadin or heparin preparations;
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study;
  • Patients who have a history of another primary ≤3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of uterine;
  • Female patients who are pregnant or breastfeeding, or adults of who are not using effective methods. If barrier contraceptives are being used, these must be continued throughout the study by both sexes. Oral contraceptives are not acceptable;
  • Patients who are using other agents or who had received investigational drugs ≤4 weeks prior to study treatment start; Patients unwilling or unable to comply with the protocol.

Other protocol-defined inclusion/exclusion may apply

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    RAD001

    Drug: RAD001

Interventions

  • DrugRAD001

    Also known as: Everolimus

06

What researchers measure

Primary outcomes

  1. PFS (Progression-Free Survival)

    the time from the date of the start of RAD001 treatment to the date of the first documented disease progression or death due to any cause

    Time frame: Approximately 4 years

Secondary outcomes

  1. Disease Control Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR]);

    The disease control rate was based on the data as per local radiological review following the RECIST criteria. The disease control rate is defined as the proportion of patients with CR, PR, or SD and was summarized in terms of percentage with 95% exact Clopper-Pearson CIs

    Time frame: Approximately 4 years

  2. Objective Response Rate (ORR; Where ORR = CR + PR)

    The overall tumor response was based on the data as per local radiological review, following RECIST criteria. The ORR is defined as the proportion of patients with CR or PR and was summarized in terms of percentage with 95% exact Clopper-Pearson CIs

    Time frame: Approximately 4 years

  3. Duration of Response (DOR)

    The DOR analysis applied only to patients whose overall response was CR or PR and was defined as the time from onset of response (CR/PR) to progression or death from any cause

    Time frame: Approximately 4 years

  4. Overall Survival

    Overall survival is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact.

    Time frame: Approximately 4 years

07

Results

Posted Jun 24, 2019

Participant flow

Participant flow — Overall Study
MilestoneRAD001
Started142
Completed4
Not completed138
Withdrew: Adverse event20
Withdrew: Abnormal laboratory value2
Withdrew: Abnormal test procedure result1
Withdrew: Patient withdrew consent5
Withdrew: Lost to follow-up6
Withdrew: Death11
Withdrew: New cancer therapy2
Withdrew: Disease progression88
Withdrew: Protocol deviation3

Outcome measures

PrimaryPFS (Progression-Free Survival)

the time from the date of the start of RAD001 treatment to the date of the first documented disease progression or death due to any cause

Time frame:
Approximately 4 years
Reported as:
Median · Weeks
PFS (Progression-Free Survival)
WeeksRAD001
PFS (Progression-Free Survival)27.71 (21.86 to 35.29)
Statistical analysis
  • RAD001 · Median difference (net): 27.71 · 95% CI 21.86 to 35.29
SecondaryDisease Control Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR]);

The disease control rate was based on the data as per local radiological review following the RECIST criteria. The disease control rate is defined as the proportion of patients with CR, PR, or SD and was summarized in terms of percentage with 95% exact Clopper-Pearson CIs

Time frame:
Approximately 4 years
Reported as:
Number · Percentage of Participants
Disease Control Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR]);
Percentage of ParticipantsRAD001
Disease Control Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR]);74.6 (66.7 to 81.6)
SecondaryObjective Response Rate (ORR; Where ORR = CR + PR)

The overall tumor response was based on the data as per local radiological review, following RECIST criteria. The ORR is defined as the proportion of patients with CR or PR and was summarized in terms of percentage with 95% exact Clopper-Pearson CIs

Time frame:
Approximately 4 years
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR; Where ORR = CR + PR)
Percentage of participantsRAD001
Objective Response Rate (ORR; Where ORR = CR + PR)17 (7.1 to 18.5)
SecondaryDuration of Response (DOR)

The DOR analysis applied only to patients whose overall response was CR or PR and was defined as the time from onset of response (CR/PR) to progression or death from any cause

Time frame:
Approximately 4 years
Reported as:
Median · Weeks
Duration of Response (DOR)
WeeksRAD001
Duration of Response (DOR)169 (52.71 to NA)
SecondaryOverall Survival

Overall survival is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact.

Time frame:
Approximately 4 years
Reported as:
Median · Weeks
Overall Survival
WeeksRAD001
Overall SurvivalNA (116.86 to NA)
Statistical analysis
  • RAD001 · Median difference (net): 45.71 · 95% CI 31.29 to 106.43

Adverse events

Collected over Approximately 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RAD00133/142 (23.2%)48/142 (33.8%)125/142 (88%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventRAD001
PNEUMONIAInfections and infestations6/142
ANAEMIABlood and lymphatic system disorders5/142
MUCOSAL INFLAMMATIONGeneral disorders4/142
DYSPNOEARespiratory, thoracic and mediastinal disorders4/142
DIARRHOEAGastrointestinal disorders3/142
ASTHENIAGeneral disorders3/142
URINARY TRACT INFECTIONInfections and infestations3/142
DECREASED APPETITEMetabolism and nutrition disorders3/142
DEHYDRATIONMetabolism and nutrition disorders3/142
NEOPLASM PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/142
Most frequent other events
Showing 10 of 45
Most frequent other events
EventRAD001
ANAEMIABlood and lymphatic system disorders62/142
STOMATITISGastrointestinal disorders41/142
HYPERGLYCAEMIAMetabolism and nutrition disorders37/142
RASHSkin and subcutaneous tissue disorders33/142
DECREASED APPETITEMetabolism and nutrition disorders32/142
COUGHRespiratory, thoracic and mediastinal disorders31/142
FATIGUEGeneral disorders30/142
ABNORMAL LOSS OF WEIGHTMetabolism and nutrition disorders29/142
HYPERCHOLESTEROLAEMIAMetabolism and nutrition disorders25/142
MUCOSAL INFLAMMATIONGeneral disorders24/142

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RAD001
Mean55.5 ± 12.63
Sex: Female, Male
Sex: Female, Male(Participants)RAD001
Female55
Male87
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RAD001
American Indian or Alaska Native0
Asian42
Native Hawaiian or Other Pacific Islander0
Black or African American2
White71
More than one race0
Unknown or Not Reported27
08

Study locations

22 sites
  • Novartis Investigative Site
    Alger, 016000, Algeria
  • Novartis Investigative Site
    Oran, Algeria
  • Novartis Investigative Site
    Alexandria, 21131, Egypt
  • Novartis Investigative Site
    Cairo, Egypt
  • Novartis Investigative Site
    Mansoura, Egypt
  • Novartis Investigative Site
    Indore, Madhya Pradesh 452 008, India
  • Novartis Investigative Site
    Pune, Maharashtra 411013, India
  • Novartis Investigative Site
    Amman, 11941, Jordan
  • Novartis Investigative Site
    Ashrafieh, 166830, Lebanon
  • Novartis Investigative Site
    Moscow, 115478, Russian Federation
  • Novartis Investigative Site
    Samara, 443031, Russian Federation
  • Novartis Investigative Site
    Riyadh, 11211, Saudi Arabia
  • Novartis Investigative Site
    Cape Town, 7500, South Africa
  • Novartis Investigative Site
    Cape Town, 7925, South Africa
  • Novartis Investigative Site
    Durban, 4001, South Africa
  • Novartis Investigative Site
    Parktown, 2193, South Africa
  • Novartis Investigative Site
    Songkhla, Hat Yai 90110, Thailand
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
  • Novartis Investigative Site
    Tunis, Tunisie 1007, Tunisia
  • Novartis Investigative Site
    Ariana, 2080, Tunisia
  • Novartis Investigative Site
    Sousse, 4000, Tunisia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2009 to primary completion in Jun 2017, 90 months.

Results were first posted in Jun 2019, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2010
First posted
Sep 22, 2010
StartActual
Nov 11, 2009
Primary completionActual
Jun 6, 2017
CompletionActual
Jul 1, 2017
Results first posted
Jun 24, 2019
Last update
Jun 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01206764
Responsible party
Sponsor
First posted
Sep 22, 2010
Start date
Nov 11, 2009
Primary completion
Jun 6, 2017
Completion
Jul 1, 2017
Results posted
Jun 24, 2019
Last update
Jun 24, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion